Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality.
OBJECTIVE
A limited range of antibiotic classes are available for treatment of Chryseobacterium meningosepticum infections. Although the role of C. meningosepticum in newborn infections and immunocompromised hosts has been recognized, clinical data detailing these infections remain limited. This retrospective study investigated the risk factors for mortality in patients with C. meningosepticum infections and the antibiotic susceptibility of clinical isolates.


METHODS
Information on demographic characteristics, clinical parameters, antibiotic treatment, and outcomes was collected. Statistical significance of potential prognostic parameters was analyzed by Fisher's exact test. The antimicrobial susceptibility of 19 isolates to seven antibiotics was determined, and susceptibility results were presented as minimal inhibitory concentration (MIC) range, MIC at which 50% of isolates were inhibited (MIC(50)), and MIC at which 90% of isolates were inhibited (MIC(90)).


RESULTS
Hypoalbuminemia (<2.5 g/dL) [p=0.02] and increased pulse rate (p=0.008) at the onset of infection, and presence of an indwelling central venous line (p=0.04) were associated with poor outcomes. Use of appropriate antibiotics was not significantly associated with the clinical outcome (p=0.21). MIC values of levofloxacin (MIC(50)/(90), 0.12/2 microg/mL) were lower than those of ciprofloxacin (0.5/4 microg/mL).


CONCLUSIONS
Hypoalbuminemia, increased pulse rate at the onset of infection and presence of central venous line infection were associated with a poor outcome in patients with C. meningosepticum.
Hung
Po-Pin
PP
Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Lin
Yu-Hui
YH
Lin
Chin-Fu
CF
Liu
Meei-Fang
MF
Shi
Zhi-Yuan
ZY
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D045247:Chryseobacterium / Q000187:drug effects* / Q000302:isolation & purification; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D045826:Flavobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality*; D006801:Humans; D007223:Infant; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin